Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
Mount Sinai Hospital · University of Toronto · +3 more institutions
Abstract
Metformin, an insulin-lowering agent, has been associated with decreased cancer risk in epidemiologic studies in diabetic patients. We performed a comprehensive literature search and meta-analysis of epidemiologic studies to assess the effect of metformin on cancer incidence and mortality in diabetic patients, using Pubmed, ISI Web of Science, Embase, and the Cochrane library until May 2009, with no language or time restrictions. Independent reports with sufficient information to allow risk estimation of cancer risk/mortality and a measure of uncertainty were reviewed and cross-checked independently by three investigators. Eleven studies were selected for relevance in terms of intervention, population studied,…
Citation impact
- FWCI
- 29.40
- Percentile
- 100%
- References
- 77
Authors
7- ADAndrea DeCensiCorresponding
Mount Sinai Hospital, University of Toronto, Lunenfeld-Tanenbaum Research Institute, Princess Margaret Cancer Centre, European Institute of Oncology
- MPMatteo Puntoni
Mount Sinai Hospital, University of Toronto, Lunenfeld-Tanenbaum Research Institute, Princess Margaret Cancer Centre, European Institute of Oncology
- PJPamela J. Goodwin
Mount Sinai Hospital, University of Toronto, Lunenfeld-Tanenbaum Research Institute, Princess Margaret Cancer Centre, European Institute of Oncology
- MCMassimiliano Cazzaniga
Mount Sinai Hospital, University of Toronto, Lunenfeld-Tanenbaum Research Institute, Princess Margaret Cancer Centre, European Institute of Oncology
- AGAlessandra Gennari
Mount Sinai Hospital, University of Toronto, Lunenfeld-Tanenbaum Research Institute, Princess Margaret Cancer Centre, European Institute of Oncology
Topics & keywords
- Medicine
- Metformin
- Cancer
- Internal medicine
- Population
- Oncology
- Incidence (geometry)
- Relative risk
- Good health and well-being